US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Pacer WealthShield ETF

33.36

-0.2427-0.72%

Post-market: 33.360.00000.00%16:10 EDT

Volume:235

Turnover:8K

Market Cap:25.02M

PE:- -

High:33.36

Open:33.60

Low:33.36

Close:33.60

52wk High:33.83

52wk Low:30.85

Shares:750.00K

Float Shares:750.00K

Volume Ratio:0.26

T/O Rate:0.03%

Dividend:0.42

Dividend Rate:1.27%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Press Release: Aardvark Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates

Press Release: Relmada Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

Rhythm Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Update

Stock-bond Correlations Seen Rising

Rhythm Pharmaceuticals Announces Multiple New Data Presentations from MC4R Agonists in Acquired Hypothalamic Obesity (HO), Bardet-Biedl Syndrome (BBS) and Prader-Willi Syndrome (PWS) at ENDO 2026

Rhythm Pharmaceuticals: Buy Rating Reiterated on Promising PWS Data and Large Market Opportunity; $105 Price Target Unchanged

Rhythm Pharmaceuticals (RYTM) Stock After Positive Phase 2 PWS Data What Does The Valuation Suggest

Simply Wall St.

Rhythm Pharmaceuticals to Announce Interim Six-Month Phase 2 Results Evaluating Setmelanotide in Patients with Prader-Willi Syndrome

Press Release: Relmada Therapeutics Appoints CNS Drug Development Veteran Michael Quirk as Senior Advisor for Sepranolone Program

Rhythm Pharmaceuticals Announces Seven Abstracts Accepted for Presentation at ENDO 2026

FDA Imposes Full Clinical Hold on Aardvark's PWS Drug Candidate, Triggering Sharp Stock Decline

Aardvark Therapeutics Plans to Unblind HERO and OLE Data to Inform Path Forward Following FDA Clinical Hold

Press Release: Aardvark Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates

Rhythm Pharmaceuticals Reports First Quarter 2026 Financial Results and Business Update

Press Release: Neurocrine to Acquire Soleno Therapeutics, Expanding Its Endocrinology and Rare Disease Portfolio

Aardvark Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates

AFT Pharmaceuticals Wins Court of Appeal Case Over Pascomer Profits

MT Newswires Live

Soleno Therapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Update on U.S. Launch of VYKAT™ XR

Press Release: Harmony Biosciences Reports Strong 2025 Financial Results and Reiterates 2026 Net Revenue Guidance of Over $1 Billion

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/stock/PWS/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"PWS","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PWS\",,,,,undefined,":{"symbol":"PWS","market":"US","secType":"STK","nameCN":"Pacer WealthShield ETF","latestPrice":33.3575,"timestamp":1787601600000,"preClose":33.6002,"halted":0,"volume":235,"hourTrading":{"tag":"盘后","latestPrice":33.3575,"preClose":33.3575,"latestTime":"16:10 EDT","volume":6,"amount":200.145,"timestamp":1787602204918,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.007223171290647057,"floatShares":750001,"shares":750001,"eps":0,"marketStatus":"Post-Mkt","change":-0.2427,"latestTime":"08-24 19:19:29 EDT","open":33.6002,"high":33.3575,"low":33.3575,"amount":7832,"amplitude":0,"askPrice":49.93,"askSize":200,"bidPrice":16.65,"bidSize":200,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1787616000000},"marketStatusCode":4,"adr":0,"adrRate":0,"exchange":"CBOE","adjPreClose":33.6002,"sharesOutstanding":950000,"nav":33.5,"aum":25125000,"dividendRate":0.012693,"bidAskSpread":0.001851,"postHourTrading":{"tag":"盘后","latestPrice":33.3575,"preClose":33.3575,"latestTime":"16:10 EDT","volume":6,"amount":200.145,"timestamp":1787602204918,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.258185},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PWS\",,,,,undefined,":{"symbol":"PWS","floatShares":750001,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.258185,"shares":750001,"dividePrice":0.4234,"high":33.3575,"amplitude":0,"preClose":33.6002,"low":33.3575,"week52Low":30.85,"pbRate":"--","week52High":33.83,"institutionHeld":0,"latestPrice":33.3575,"eps":0,"divideRate":0.012693,"volume":235,"delay":0,"ttmEps":0,"open":33.6002,"prevYearClose":32.3237,"prevWeekClose":33.6002,"prevMonthClose":32.1284,"prevQuarterClose":32.8173,"fiveDayClose":33.6272,"twentyDayClose":32.429,"sixtyDayClose":31.9096},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PWS\",params:#limit:5,,,undefined,":[{"date":"2026-06-04","symbol":"PWS","amount":0.0682,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-06-04","defaultRemindTime":1780579800000,"name":"Pacer WealthShield ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-06-08","payableDate":"2026-06-04","currency":"USD","dateTimestamp":1780545600000,"payDate":"2026-06-08"},{"date":"2026-03-05","symbol":"PWS","amount":0.016362,"announcedDate":"2026-03-04","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-03-05","defaultRemindTime":1772721000000,"name":"Pacer WealthShield ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-03-09","payableDate":"2026-03-05","currency":"USD","dateTimestamp":1772686800000,"payDate":"2026-03-09"},{"date":"2025-12-30","symbol":"PWS","amount":0.25921895,"announcedDate":"2025-12-29","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-30","defaultRemindTime":1767105000000,"name":"Pacer WealthShield ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-01-05","payableDate":"2025-12-30","currency":"USD","dateTimestamp":1767070800000,"payDate":"2026-01-05"},{"date":"2025-09-04","symbol":"PWS","amount":0.0796608,"announcedDate":"2025-09-03","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-09-04","defaultRemindTime":1756992600000,"name":"Pacer WealthShield ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-09-10","payableDate":"2025-09-04","currency":"USD","dateTimestamp":1756958400000,"payDate":"2025-09-10"},{"date":"2025-06-05","symbol":"PWS","amount":0.116206,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-06-05","defaultRemindTime":1749130200000,"name":"Pacer WealthShield ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-06-11","payableDate":"2025-06-05","currency":"USD","dateTimestamp":1749096000000,"payDate":"2025-06-11"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PWS\",market:\"US\",,,undefined,":[{"executeDate":"2018-03-27","recordDate":"2018-03-28","paymentDate":"2018-03-29","value":0.0522982,"currency":"USD"},{"executeDate":"2018-06-26","recordDate":"2018-06-27","paymentDate":"2018-06-28","value":0.0481106,"currency":"USD"},{"executeDate":"2018-09-25","recordDate":"2018-09-26","paymentDate":"2018-09-27","value":0.1105742,"currency":"USD"},{"executeDate":"2018-12-24","recordDate":"2018-12-26","paymentDate":"2018-12-27","value":0.0682115,"currency":"USD"},{"executeDate":"2019-03-26","recordDate":"2019-03-27","paymentDate":"2019-03-28","value":0.1385698,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"PWS\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"PWS\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2658451129","title":"Press Release: Aardvark Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2658451129","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658451129?lang=en_us&edition=fundamental","pubTime":"2026-08-12 04:53","pubTimestamp":1786481580,"startTime":"0","endTime":"0","summary":"and the OLE  trial to assess the totality of. available efficacy and safety data and to support an informed. determination of next steps for the ARD-101 program. In June 2026, the. Company terminated the HERO and the OLE trial and does not currently. intend to resume these trials as previously designed.-- In May 2026, the Company announced that the U.S. Food and Drug. Administration  placed a full clinical hold on its investigational. new drug application  for ARD-101, related to the Company's. previously announced voluntary pause. The clinical hold applies to all. previously ongoing clinical studies under the IND, including the Phase 3. HERO trial evaluating ARD-101 for the treatment of hyperphagia in. patients with Prader-Willi Syndrome  and the Phase 3 OLE trial.Second Quarter 2026 Financial Highlights-- Cash Position: As of June 30, 2026, Aardvark had cash, cash equivalents. and short-term investments of $73.9 million, compared to $91.2 million as. of March 31, 2026. Based on curre","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","IDNA","NVIB","IND","MEDX","GDOC","HYLG","PWS","BMED","AARD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657657184","title":"Press Release: Relmada Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2657657184","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657657184?lang=en_us&edition=fundamental","pubTime":"2026-08-07 04:05","pubTimestamp":1786046700,"startTime":"0","endTime":"0","summary":"-- Advancing NDV-01 toward IND filing expected by year-end 2026 with GMP. manufacturing of clinical trial material underway. Initiation of the. Phase 3 RESCUE registrational program upon IND clearance.-- Sepranolone IND filing expected by year-end 2026 and initiation of Phase. 2 proof-of-concept study in Prader-Willi Syndrome upon IND clearance.-- Strengthened the leadership team with appointment of Bipin Dalmia as. -- Added to the Russell 2000 and Russell 3000 Indexes effective June. -- Cash balance of $217.7 million as of June 30, 2026, expected to fund. operations through 2029, including completion of the NDV-01 Phase 3","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4567","IE00BKVL7J92.USD","LU2237443549.SGD","LU1721428933.USD","IE00BN0W2W23.USD","IE00B1BXHZ80.USD","BK4121","LENZ","LU0882574139.USD","LU1721429402.USD","PWS","LU2237443895.HKD","IE00BHPRN162.USD","LU2413666426.HKD","IE00BZ1G4Q59.USD","IE00BN0W2V16.EUR","LU2092937221.SGD","LU1543694498.USD","BK4006","CMC","LU2746668461.USD","LU1721429741.USD","R","BK4232","EES","BK4539","BK4505","IE00BN0W2T93.GBP","LU2089279066.USD","LU2237443978.SGD","RLMD","BK4139","LU2746668974.SGD","IND","LU0170899867.USD","LU0971096721.USD","IE00BFXG1179.USD","LU2237443465.HKD","ALLO","PSIL","LU2041044095.USD","BK4588","BK4585","BK4007","A","LU0149725797.USD","LU2413666699.HKD","LU2229751404.USD","LU2237443622.USD","LU0347712357.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656558874","title":"Rhythm Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2656558874","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656558874?lang=en_us&edition=fundamental","pubTime":"2026-08-04 19:01","pubTimestamp":1785841260,"startTime":"0","endTime":"0","summary":"-- U.S. launch of IMCIVREE (setmelanotide) for acquired hypothalamic obesity (HO) starts strong with more than 400 patient start forms since FDA approval as of June 30, 2026 ---- Second quarter 2026 n","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/04/3338168/0/en/Rhythm-Pharmaceuticals-Reports-Second-Quarter-2026-Financial-Results-and-Business-Update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2237443465.HKD","LU0971096721.USD","LU2237443895.HKD","LU2237443549.SGD","LU2237443382.USD","VUS","IE00BKVL7J92.USD","IE00B1BXHZ80.USD","LU0882574139.USD","LU2237443978.SGD","CMC","LU0170899867.USD","PWS","LU2746668461.USD","IE00BHPRN162.USD","LU2746668974.SGD","BK4006","LU0267386448.USD","BK4201","IE00BZ1G4Q59.USD","LU0149725797.USD","LU1363072403.SGD","LU2237443622.USD","IE00BFXG1179.USD","EC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653226313","title":"Stock-bond Correlations Seen Rising","url":"https://stock-news.laohu8.com/highlight/detail?id=2653226313","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653226313?lang=en_us&edition=fundamental","pubTime":"2026-07-21 13:26","pubTimestamp":1784611560,"startTime":"0","endTime":"0","summary":"0526 GMT - The recent volatility in inflation leading economic indicators  is poised to push up stock-bond correlations, continuing a macro environment where bonds are less effective as equity diversifiers, Variant Perception says in a note. Variant's leading indicator for stock-bond correlations is ticking higher again, signaling positive expected correlations ahead, it says. \"This has been driven by rising volatility of our inflation LEI,\" it says. More frequent inflation shocks tend to restrict central bank policy flexibility, resulting in slower policy responses to negative shocks and driving up stock-bond correlations, it adds.  Dow Jones NewswiresJuly 21, 2026 01:26 ET Copyright  2026 Dow Jones & Company, Inc.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CGUS","IMCG","AOK","DFUV","EAOM","FIRS","GAL","DIVZ","PWS","EQRR","HIDV","FLV","FT","BAMA","BAMO","MODL","CGDV","EES","NDAA","QVOY","LGH","ADPV","ELM","MRSK","PRVS","ARP","EAOR","ITDJ","BSR","DECU","CLSM","CGUI","LCG","FXD","BNDW","CLIX","MAPP","CDC","MDLV","IUS","ITDB","EAOA","DRSK","BKDV","ILCV","MPAY","PLGI","AOR","PSC","DDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643785500","title":"Rhythm Pharmaceuticals Announces Multiple New Data Presentations from MC4R Agonists in Acquired Hypothalamic Obesity (HO), Bardet-Biedl Syndrome (BBS) and Prader-Willi Syndrome (PWS) at ENDO 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2643785500","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643785500?lang=en_us&edition=fundamental","pubTime":"2026-06-16 04:01","pubTimestamp":1781553660,"startTime":"0","endTime":"0","summary":"-- Setmelanotide therapy achieved robust, sustained and clinically significant weight loss in patients with acquired HO at 2.5 years --  -- Bivamelagon therapy achieved progressive reductions in BMI a","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/15/3312120/0/en/Rhythm-Pharmaceuticals-Announces-Multiple-New-Data-Presentations-from-MC4R-Agonists-in-Acquired-Hypothalamic-Obesity-HO-Bardet-Biedl-Syndrome-BBS-and-Prader-Willi-Syndrome-PWS-at-E.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AVP","ENDO","BK4201","PWS","VUS","BK4183","EC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643227716","title":"Rhythm Pharmaceuticals: Buy Rating Reiterated on Promising PWS Data and Large Market Opportunity; $105 Price Target Unchanged","url":"https://stock-news.laohu8.com/highlight/detail?id=2643227716","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643227716?lang=en_us&edition=fundamental","pubTime":"2026-06-15 18:35","pubTimestamp":1781519743,"startTime":"0","endTime":"0","summary":"In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Rhythm Pharmaceuticals, with a price target of $105.00. R...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/rhythm-pharmaceuticals-buy-rating-reiterated-on-promising-pws-data-and-large-market-opportunity-105-price-target-unchanged-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/rhythm-pharmaceuticals-buy-rating-reiterated-on-promising-pws-data-and-large-market-opportunity-105-price-target-unchanged-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PWS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643024272","title":"Rhythm Pharmaceuticals (RYTM) Stock After Positive Phase 2 PWS Data What Does The Valuation Suggest","url":"https://stock-news.laohu8.com/highlight/detail?id=2643024272","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643024272?lang=en_us&edition=fundamental","pubTime":"2026-06-15 02:13","pubTimestamp":1781460825,"startTime":"0","endTime":"0","summary":"Phase 2 PWS data and what it could mean for Rhythm Pharmaceuticals stock\nRhythm Pharmaceuticals (RYTM) recently reported six month interim Phase 2 data for setmelanotide in Prader Willi syndrome, highlighting clinically meaningful changes in BMI, fat mass, hyperphagia, and anxiety, and outlined plans to move into Phase 3 development.\nSee our latest analysis for Rhythm Pharmaceuticals.\nThe latest PWS data arrives after a mixed share price stretch, with the stock down 15.84% year to date on a...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rytm/rhythm-pharmaceuticals/news/rhythm-pharmaceuticals-rytm-stock-after-positive-phase-2-pws","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rytm/rhythm-pharmaceuticals/news/rhythm-pharmaceuticals-rytm-stock-after-positive-phase-2-pws","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["RYTM","BK4588","PWS","BK4585","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643185082","title":"Rhythm Pharmaceuticals to Announce Interim Six-Month Phase 2 Results Evaluating Setmelanotide in Patients with Prader-Willi Syndrome","url":"https://stock-news.laohu8.com/highlight/detail?id=2643185082","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643185082?lang=en_us&edition=fundamental","pubTime":"2026-06-13 04:01","pubTimestamp":1781294460,"startTime":"0","endTime":"0","summary":"BOSTON, June  12, 2026  (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with r","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/12/3311304/0/en/Rhythm-Pharmaceuticals-to-Announce-Interim-Six-Month-Phase-2-Results-Evaluating-Setmelanotide-in-Patients-with-Prader-Willi-Syndrome.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PWS","BK4201","VUS","AVP","EC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642286990","title":"Press Release: Relmada Therapeutics Appoints CNS Drug Development Veteran Michael Quirk as Senior Advisor for Sepranolone Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2642286990","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642286990?lang=en_us&edition=fundamental","pubTime":"2026-06-11 19:00","pubTimestamp":1781175600,"startTime":"0","endTime":"0","summary":"-- Dr. Quirk brings more than 20 years of neuroscience drug discovery and. development experience to lead Relmada's sepranolone program, building on. his tenure as Chief Scientific Officer at Sage Therapeutics.\"We are very pleased to welcome Mike to the Relmada team. His distinguished career in CNS drug discovery and development, including his leadership of research and scientific strategy at Sage Therapeutics, gives him a unique and highly relevant perspective on neuroactive steroid biology that we believe will be invaluable to the sepranolone program,\" said Sergio Traversa, Chief Executive Officer of Relmada Therapeutics.\"Sepranolone's mechanism of action -- selectively antagonizing the effects of allopregnanolone at GABA-A receptors without broadly disrupting GABAergic signaling -- represents a precise and elegant approach to modulating neural circuits that are dysregulated in compulsivity-related disorders like Prader-Willi syndrome,\" said Dr. Quirk, Senior Advisor -- Sepranolone P","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["A","LU2413666426.HKD","BK4007","LENZ","LU1721428933.USD","RLMD","LU2041044095.USD","LU1165135440.EUR","LU2092937221.SGD","LU2089279066.USD","BK4139","BK4121","LU1543694498.USD","BK4135","CNS","BK4539","ALLO","BK4585","BK4588","PWS","BK4567","LU0347712357.USD","LU2413666699.HKD","BK4505","IE00BN0W2T93.GBP","IE00BN0W2V16.EUR","IE00BN0W2W23.USD","LU2229751404.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639862225","title":"Rhythm Pharmaceuticals Announces Seven Abstracts Accepted for Presentation at ENDO 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2639862225","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2639862225?lang=en_us&edition=fundamental","pubTime":"2026-05-29 20:00","pubTimestamp":1780056000,"startTime":"0","endTime":"0","summary":"BOSTON, May  29, 2026  (GLOBE NEWSWIRE) --  Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with r","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/29/3303535/0/en/Rhythm-Pharmaceuticals-Announces-Seven-Abstracts-Accepted-for-Presentation-at-ENDO-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4201","AVP","VUS","ENDO","EC","PWS","BK4183"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1182460621","title":"FDA Imposes Full Clinical Hold on Aardvark's PWS Drug Candidate, Triggering Sharp Stock Decline","url":"https://stock-news.laohu8.com/highlight/detail?id=1182460621","media":"Deep News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1182460621?lang=en_us&edition=fundamental","pubTime":"2026-05-16 03:10","pubTimestamp":1778872232,"startTime":"0","endTime":"0","summary":"Regulatory Blow to Core Pipeline The U.S. Food and Drug Administration has issued a full clinical hold order for Aardvark Therapeutics' core investigational drug ARD-101, freezing all ongoing...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PWS","LABU","BK4585","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635251837","title":"Aardvark Therapeutics Plans to Unblind HERO and OLE Data to Inform Path Forward Following FDA Clinical Hold","url":"https://stock-news.laohu8.com/highlight/detail?id=2635251837","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635251837?lang=en_us&edition=fundamental","pubTime":"2026-05-15 04:01","pubTimestamp":1778788860,"startTime":"0","endTime":"0","summary":"SAN DIEGO, May  14, 2026  (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark or the Company) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecu","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/14/3295315/0/en/Aardvark-Therapeutics-Plans-to-Unblind-HERO-and-OLE-Data-to-Inform-Path-Forward-Following-FDA-Clinical-Hold.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","HERO","IND","AARD","PWS","BK4585","BK4007","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633410771","title":"Press Release: Aardvark Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2633410771","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633410771?lang=en_us&edition=fundamental","pubTime":"2026-05-07 20:00","pubTimestamp":1778155200,"startTime":"0","endTime":"0","summary":"ARD-101 and ARD-201 programs on voluntary pause; further guidance expected in Q2 2026. $91.2 million in cash, cash equivalents and short-term investments as of March 31, 2026, supports projected operations into mid-2027. SAN DIEGO, May 07, 2026  -- Aardvark Therapeutics, Inc.  , a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases, today reported financial results for the first quarter ended March 31, 2026, and provided pipeline and business updates.\"We have been working closely with the FDA to comprehensively evaluate the data following the reversible cardiac observations in the healthy volunteer trial and are committed to determining the best path forward for our programs, patients and the broader PWS community,\" said Tien Lee, M.D., Founder and Chief Executive Officer of Aardvark. \"We remain focused on establishing a clear path forward for the Phase 3 HERO t","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1989763427.SGD","LU0708994859.HKD","LU1892829315.USD","BK4007","LU1803068623.USD","PWS","LU0029864427.USD","AARD","LU1267930573.SGD","BK4126","LU0054578231.USD","LU0310800379.SGD","LU0211328371.USD","LU0310799852.SGD","CCK","HERO","LU0211327993.USD","LU1989763690.USD","LU0128525929.USD","LU1267930490.SGD","LU0029874061.USD","LU0128526141.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633140419","title":"Rhythm Pharmaceuticals Reports First Quarter 2026 Financial Results and Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2633140419","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633140419?lang=en_us&edition=fundamental","pubTime":"2026-05-05 19:00","pubTimestamp":1777978800,"startTime":"0","endTime":"0","summary":"-- IMCIVREE (setmelanotide) launched in the U.S. for acquired hypothalamic obesity; more than 150 patient start forms received in the first six weeks following FDA approval on March 19, 2026 -- -- Fir","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/05/3287506/0/en/Rhythm-Pharmaceuticals-Reports-First-Quarter-2026-Financial-Results-and-Business-Update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4201","BK4087","PWS","VUS","EC","CHMP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625367500","title":"Press Release: Neurocrine to Acquire Soleno Therapeutics, Expanding Its Endocrinology and Rare Disease Portfolio","url":"https://stock-news.laohu8.com/highlight/detail?id=2625367500","media":"Dow Jones","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625367500?lang=en_us&edition=fundamental","pubTime":"2026-04-06 19:00","pubTimestamp":1775473200,"startTime":"0","endTime":"0","summary":"VYKAT XR  is the First and Only FDA Approved Treatment for Hyperphagia in Prader-Willi Syndrome and Represents a Transformative Therapy. Expands Neurocrine's High-Growth Commercial Portfolio to Three First-in-Class Medicines Including INGREZZA  and CRENESSITY . Establishes a Durable Platform for Long-Term Revenue Growth and Value Creation, Supported by Strong VYKAT XR Intellectual Property Estate Expected to Extend into the mid-2040s. Neurocrine to Host Conference Call at 8:00 AM ET Today to Discuss Transaction. SAN DIEGO and REDWOOD CITY, Calif., April 6, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc.  and Soleno Therapeutics, Inc.  today announced that Neurocrine has entered into a definitive agreement to acquire Soleno for $53.00 per share in cash, representing a total transaction equity value of $2.9 billion.\"Neurocrine is the right strategic partner to expand the reach of VYKAT XR in the Prader-Willi syndrome community given their experience in endocrinology and rare disease an","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4175","BK4604","LU0792757196.USD","LU0320765992.SGD","BK4099","LU2324357040.USD","NBIX","LU0889566641.SGD","BK4555","LU1267930813.SGD","LU0052756011.USD","LU2065171311.SGD","LU0154245673.USD","LU2065170008.USD","LU0310799852.SGD","LU0006061336.USD","LU1267930490.SGD","BK4585","LU0211327993.USD","SLNO","BK4588","LU0211328371.USD","SG9999001440.SGD","LU0889565916.HKD","LU0128525689.USD","LU0823416689.USD","BK4022","R","LU0310800965.SGD","TM","LU0072461881.USD","LU0162691827.USD","CAH","BK4139","LU0154236417.USD","BK4232","LU1880398471.USD","LU1880398554.USD","PWS","LU2065171402.SGD","LU2065169927.USD","LU0109394709.USD","LU1267930227.SGD","LU1571399168.USD","03160","LU0154245756.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621084925","title":"Aardvark Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2621084925","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621084925?lang=en_us&edition=fundamental","pubTime":"2026-03-24 04:05","pubTimestamp":1774296300,"startTime":"0","endTime":"0","summary":"Voluntary pause of the Phase 3 HERO and OLE trials evaluating ARD-101 for the treatment of hyperphagia in individuals with Prader-Willi Syndrome, further guidance on the program expected in Q2 2026 AR","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/23/3260833/0/en/Aardvark-Therapeutics-Reports-Fourth-Quarter-and-Full-Year-2025-Financial-Results-and-Provides-Business-Updates.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0211328371.USD","AARD","LU1267930573.SGD","LU1892829315.USD","LU0708994859.HKD","PWS","BK4126","HERO","CCK","LU0310799852.SGD","LU0310800379.SGD","LU0054578231.USD","LU0029874061.USD","BK4007","LU0029864427.USD","LU1267930490.SGD","LU0211327993.USD","LU0128526141.USD","LU1803068623.USD","LU0128525929.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618692420","title":"AFT Pharmaceuticals Wins Court of Appeal Case Over Pascomer Profits","url":"https://stock-news.laohu8.com/highlight/detail?id=2618692420","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618692420?lang=en_us&edition=fundamental","pubTime":"2026-03-09 08:16","pubTimestamp":1773015366,"startTime":"0","endTime":"0","summary":"AFT Pharmaceuticals  said that the court of appeal has dismissed PBL Solutions' bid to claim a share of profits from the company's use of its topical skin medicine Pascomer for treating port wine stains , according to a Monday filing with the Australian and New Zealand bourses.The ruling allows the company to retain full profits from Pascomer's use in treating non-orphan conditions like PWS, per the filing.PBL, holding a 35% stake in AFT Orphan Pharmaceuticals, will receive 35% of any profits from Pascomer orphan drug applications, the filing said.PBL and the company will share the appeal costs, and the company does not expect the judgment to materially affect its fiscal year 2026 earnings guidance, the filing added.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["AFP.AU","PWS","BK7096","AFT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614050774","title":"Soleno Therapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Update on U.S. Launch of VYKAT™ XR","url":"https://stock-news.laohu8.com/highlight/detail?id=2614050774","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614050774?lang=en_us&edition=fundamental","pubTime":"2026-02-26 05:01","pubTimestamp":1772053260,"startTime":"0","endTime":"0","summary":"REDWOOD CITY, Calif., Feb.  25, 2026  (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare disease","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/02/25/3244960/0/en/Soleno-Therapeutics-Reports-Fourth-Quarter-and-Full-Year-2025-Financial-Results-and-Provides-Update-on-U-S-Launch-of-VYKAT-XR.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PWS","SLNO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2613719807","title":"Press Release: Harmony Biosciences Reports Strong 2025 Financial Results and Reiterates 2026 Net Revenue Guidance of Over $1 Billion","url":"https://stock-news.laohu8.com/highlight/detail?id=2613719807","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613719807?lang=en_us&edition=fundamental","pubTime":"2026-02-24 20:30","pubTimestamp":1771936200,"startTime":"0","endTime":"0","summary":"WAKIX 2025 Net Revenue of $868.5 Million; 2026 WAKIX Net Revenue Guidance of $1.0 -- $1.04 Billion on Track for Blockbuster Status in Narcolepsy. Recently Completed Settlements with 3 Additional Generic Filers Toward Goal of Securing WAKIX Franchise. Pitolisant GR NDA Submission on Track for Q2 2026; Extends the Pitolisant Franchise into the 2040s. Exploring New Opportunities to Broaden the Pitolisant Franchise Beyond Orphan/Rare into Larger CNS Indications. Potential Best-In-Class Orexin-2 Agonist  Phase 1 Trial Ongoing; Clinical Data Expected in Mid-2026. Fourth Quarter and Full Year 2025 Net Product Revenue for WAKIX. --  Net product revenue for the quarter ended December 31, 2025, was $243.8. million, compared to $201.3 million for the same period in 2024. 8,500 patients in Q4 2025; representing the third consecutive quarter of. --  Net revenue projected between $1.0 billion to $1.04 billion for the","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","PWS","BK4022","R","HRMY","BK4232"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":19,"code":"91000000","status":"200"}]}}